HDR-brachytherapy boost for residual tumour after external beam radiotherapy in patients with tracheal malignancies.
Seven inoperable patients with tracheal neoplasms received a high dose rate (HDR) brachytherapy boost (median 15 Gy, single dose 3-5 Gy) for residual tumour after external beam radiotherapy (median 50 Gy, 5 x 2 Gy/week). The median actuarial survival was 34.3 months. The 1-, 2- and 3-year actuarial survival rates were 85.7%, 85.7% and 32%. Local control was obtained in 5/7 patients. Late toxicity occurred in three patients (stenosis n = 2, hemorrhage n = 1). Our data indicate, that a HDR brachytherapy boost is effective and feasible.
Harms
W
W
Department of Clinical Radiology, University of Heidelberg, Germany.
Latz
D
D
Becker
H
H
Herth
F
F
Schraube
P
P
Krempien
R
R
Wannenmacher
M
M
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D001999:Bronchoscopy; D003528:Carcinoma, Adenoid Cystic / Q000532:radiotherapy / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000601:surgery; D002813:Chondrosarcoma / Q000532:radiotherapy / Q000601:surgery; D018450:Disease Progression; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D018365:Neoplasm, Residual / Q000532:radiotherapy; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012074:Remission Induction; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D014133:Tracheal Diseases / Q000209:etiology; D014134:Tracheal Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D014135:Tracheal Stenosis / Q000209:etiology